BridgeBio Pharma, Inc. (BBIO)
78.17
-1.37
(-1.72%)
USD |
NASDAQ |
Nov 12, 16:00
77.76
-0.41
(-0.52%)
After-Hours: 20:00
BridgeBio Pharma Enterprise Value : 18.15B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 18.15B |
| November 11, 2026 | 18.42B |
| November 10, 2026 | 18.25B |
| November 09, 2026 | 18.10B |
| November 06, 2026 | 17.39B |
| November 05, 2026 | 17.38B |
| November 04, 2026 | 18.09B |
| November 03, 2026 | 17.34B |
| November 02, 2026 | 17.53B |
| October 30, 2026 | 17.52B |
| October 29, 2026 | 16.69B |
| October 28, 2026 | 16.71B |
| October 27, 2026 | 16.42B |
| October 26, 2026 | 16.18B |
| October 23, 2026 | 16.26B |
| October 22, 2026 | 16.18B |
| October 21, 2026 | 16.10B |
| October 20, 2026 | 16.07B |
| October 19, 2026 | 16.14B |
| October 16, 2026 | 15.84B |
| October 15, 2026 | 15.98B |
| October 14, 2026 | 15.55B |
| October 13, 2026 | 15.23B |
| October 12, 2026 | 15.71B |
| October 09, 2026 | 15.64B |
| Date | Value |
|---|---|
| October 08, 2026 | 15.57B |
| October 07, 2026 | 15.86B |
| October 06, 2026 | 15.95B |
| October 05, 2026 | 15.79B |
| October 02, 2026 | 16.01B |
| October 01, 2026 | 15.94B |
| September 30, 2026 | 15.72B |
| September 29, 2026 | 15.57B |
| September 28, 2026 | 15.70B |
| September 25, 2026 | 15.50B |
| September 24, 2026 | 15.63B |
| September 23, 2026 | 15.52B |
| September 22, 2026 | 16.21B |
| September 21, 2026 | 15.69B |
| September 18, 2026 | 15.70B |
| September 17, 2026 | 15.84B |
| September 16, 2026 | 16.03B |
| September 15, 2026 | 16.05B |
| September 14, 2026 | 16.83B |
| September 11, 2026 | 16.84B |
| September 10, 2026 | 16.85B |
| September 09, 2026 | 17.55B |
| September 08, 2026 | 17.29B |
| September 04, 2026 | 17.31B |
| September 03, 2026 | 17.42B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Ionis Pharmaceuticals, Inc. | 4.834B |
| Pfizer Inc. | 213.03B |
| Cytokinetics, Inc. | 7.958B |
| Vertex Pharmaceuticals, Inc. | 137.73B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -60.50M |
| Revenue (Quarterly) | 353.17M |
| Total Expenses (Quarterly) | 409.88M |
| EPS Diluted (Quarterly) | -0.4234 |
| Gross Profit Margin (Quarterly) | 94.11% |
| Profit Margin (Quarterly) | -17.13% |
| Earnings Yield | -3.89% |
| Normalized Earnings Yield | -3.909 |